Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity

被引:33
作者
Uddin, Sharif
Borrow, Ray
Haeney, Mansel R.
Moran, Andrew
Warrington, Rosalind
Balmer, Paul
Arkwright, Peter D.
机构
[1] Univ Manchester, Booth Hall Childrens Hosp, Manchester M9 7AA, Lancs, England
[2] Manchester Royal Infirm, Hlth Protect Agcy, Manchester M13 9WL, Lancs, England
[3] Hope Hosp, Dept Immunol, Salford M6 8HD, Lancs, England
关键词
pneumococcal antibodies; serotypes; vaccine; children;
D O I
10.1016/j.vaccine.2006.03.088
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A heptavalent pneumococcal conjugate vaccine (PCV-7) protects children against invasive pneumococcal disease. The aim of this study was to evaluate immunoglobulin subclass and serotype-specific pneumococcal antibody responses to vaccination in children with a history of recurrent or severe bacterial infections. Pneumococcal IgG, IgG1, IgG2 titres were assayed by ELISA, and nine serotype concentrations measured using a nonaplex bead assay in 145 children investigated for recurrent or severe infections. Children mounted an exclusively IgG1 response after vaccination with two doses of PCV-7 and a dose of 23 valent pneumococcal polysaccharide vaccine (PPV-23), with pneumococcal IgG2 antibody titres remaining low to negligible. Measurement of serotype-specific responses demonstrated that although PCV-7 specific serotype responses increased significantly post-vaccination, specific IgG against two of the serotypes not covered by PCV-7 but only by PPV-23 remained low. We conclude that in contrast to antibody response to natural infection with Pneumococcus or pneumococcal polysaccharide vaccines which are often of a IgG2 subclass, responses in children after PCV-7 are of IgG1 subclass. Serotype-specific IgG were useful in determining the protection against specific pneumococcal strains, and showed that the PPV-23 did not broaden protection against non-PCV-7 serotypes. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5637 / 5644
页数:8
相关论文
共 24 条
[1]  
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[2]  
Anttila M, 1999, CLIN EXP IMMUNOL, V118, P402
[3]  
BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127
[4]   Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente [J].
Black, S ;
Shinefield, H ;
Baxter, R ;
Austrian, R ;
Bracken, L ;
Hansen, J ;
Lewis, E ;
Fireman, B .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (06) :485-489
[5]   Pneumococcal vaccines:: an update on current strategies [J].
Bogaert, D ;
Hermans, PWM ;
Adrian, PV ;
Rümke, HC ;
de Groot, R .
VACCINE, 2004, 22 (17-18) :2209-2220
[6]  
Borrow R, 2003, METH MOLEC MED, V87, P289
[7]   Immunity to Streptococcus pneumoniae:: factors affecting production and efficacy [J].
Casal, J ;
Tarragó, D .
CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (03) :219-224
[8]   Diagnostic criteria for primary immunodeficiencies [J].
Conley, ME ;
Notarangelo, LD ;
Etzioni, A .
CLINICAL IMMUNOLOGY, 1999, 93 (03) :190-197
[9]   The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known [J].
Fedson, DS ;
Anthony, J ;
Scott, G .
VACCINE, 1999, 17 :S11-S18
[10]   Should the new pneumococcal vaccine be used in high-risk children? [J].
Finn, A ;
Booy, R ;
Moxon, R ;
Sharland, M ;
Heath, P .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (01) :18-21